Education
About Us
Working with TipRanks
Follow Us
Qlife Holding AB (SE:QLIFE)
:QLIFE
Top Page
Qlife Holding AB
(Frankfurt:QLIFE)
33Underperform
Qlife Holding AB (QLIFE) vs. S&P 500 (SPY)
Market Cap
kr26.53M
Dividend YieldN/A
Average Volume (3M)200.54K
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth-63.52%
EPS Growth93.00%
CountrySE
Employees3
SectorConsumer Defensive
Sector Strength79
IndustryMedical - Devices
Share Statistics
EPS (TTM)-36.58
Shares Outstanding12,394,911
10 Day Avg. Volume72,454
30 Day Avg. Volume200,545
Financial Highlights & Ratios
PEG Ratio31.39
Price to Book (P/B)-10.35K
Price to Sales (P/S)0.00
P/FCF Ratio-1.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Qlife Holding AB Business Overview & Revenue Model
Company DescriptionQlife Holding AB (QLIFE) is a Swedish company operating in the healthcare and medical technology sectors. The company focuses on providing innovative diagnostic solutions through its core product, the Egoo Health platform. This platform allows users to conduct a variety of blood tests quickly and conveniently at home, providing valuable health insights without the need for traditional laboratory services.
How the Company Makes MoneyQlife Holding AB generates revenue primarily through the sale of its Egoo Health platform and associated test cartridges. Customers purchase the Egoo device, and revenue is further supplemented by the recurring sales of disposable test cartridges needed to conduct individual blood tests. The company may also engage in partnerships with healthcare providers and institutions to expand its market reach and enhance its product offerings. Additionally, Qlife could potentially benefit from licensing agreements or collaborations with other companies in the medical technology space.
Qlife Holding AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 89.00K | 244.00K | 17.99M | 39.61M | 20.75M | Gross Profit |
| 77.00K | -6.31M | -10.75M | 44.54M | 35.68M | EBIT |
| 0.00 | -168.70M | -95.74M | -54.86M | -31.32M | EBITDA |
| -29.58M | -150.50M | -78.05M | -35.13M | -19.49M | Net Income Common Stockholders |
| -55.98M | -159.96M | -93.14M | -38.80M | -20.20M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.71M | 1.66M | 14.55M | 73.46M | 20.82M | Total Assets |
| 11.64M | 39.05M | 192.65M | 193.44M | 127.19M | Total Debt |
| 8.70M | 20.25M | 52.44M | 3.70M | 3.96M | Net Debt |
| 5.98M | 18.58M | 37.89M | -69.76M | -16.86M | Total Liabilities |
| 13.07M | 62.17M | 101.50M | 30.26M | 37.64M | Stockholders Equity |
| -1.43M | -23.12M | 91.15M | 163.18M | 89.55M |
| Cash Flow | Free Cash Flow | |||
| -54.17M | -62.64M | -90.67M | -52.82M | -43.66M | Operating Cash Flow |
| -37.37M | -41.80M | -47.73M | -26.05M | -16.83M | Investing Cash Flow |
| -16.80M | -20.84M | -42.94M | -26.77M | -26.83M | Financing Cash Flow |
| 55.23M | 49.00M | 32.73M | 105.42M | 58.91M |
Qlife Holding AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $8.78B | 14.76 | 5.05% | 174.28% | 3.62% | 3.48% | |
61 Neutral | €10.38M | ― | ― | 96.10% | 94.79% | ||
46 Neutral | kr229.77M | ― | -102.63% | ― | -0.61% | 54.19% | |
43 Neutral | kr128.89M | ― | -151.03% | ― | 27.78% | 43.32% | |
34 Underperform | €58.48M | ― | -82.35% | ― | 127.04% | 92.31% | |
33 Underperform | kr26.53M | ― | ― | -63.52% | 93.00% |
* Consumer Defensive Sector Average
Performance Comparison
SE:QLIFE
Qlife Holding AB
2.14
0.78
57.70%
SE:ACARIX
Acarix AB
0.22
-0.07
-25.52%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
2.90
-11.32
-79.60%
SE:S2M
S2Medical AB Class B
0.01
-0.02
-66.67%
SE:SCIB
SciBase Holding AB
0.38
0.09
31.38%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.